243 related articles for article (PubMed ID: 24045880)
21. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
22. Dopaminergic mechanisms underlying the expression of antipsychotic-induced dopamine supersensitivity in rats.
Servonnet A; Allain F; Gravel-Chouinard A; Hernandez G; Bourdeau Caporuscio C; Legrix M; Lévesque D; Rompré PP; Samaha AN
Neuropharmacology; 2021 Oct; 197():108747. PubMed ID: 34364897
[TBL] [Abstract][Full Text] [Related]
23. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
Stahl SM
J Clin Psychiatry; 2001 Nov; 62(11):841-2. PubMed ID: 11775041
[TBL] [Abstract][Full Text] [Related]
24. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
25. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
[TBL] [Abstract][Full Text] [Related]
26. Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).
Seeman P
Schizophr Res; 2009 Apr; 109(1-3):191-2. PubMed ID: 19171464
[No Abstract] [Full Text] [Related]
27. Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.
Handley R; Zelaya FO; Reinders AA; Marques TR; Mehta MA; O'Gorman R; Alsop DC; Taylor H; Johnston A; Williams S; McGuire P; Pariante CM; Kapur S; Dazzan P
Hum Brain Mapp; 2013 Feb; 34(2):272-82. PubMed ID: 22451196
[TBL] [Abstract][Full Text] [Related]
28. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
Wood MD; Scott C; Clarke K; Westaway J; Davies CH; Reavill C; Hill M; Rourke C; Newson M; Jones DN; Forbes IT; Gribble A
Eur J Pharmacol; 2006 Sep; 546(1-3):88-94. PubMed ID: 16925992
[TBL] [Abstract][Full Text] [Related]
29. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
[TBL] [Abstract][Full Text] [Related]
30. Hyperprolactinemia with aripiprazole: understanding the paradox.
Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania.
Mavrikaki M; Nomikos GG; Panagis G
Int J Neuropsychopharmacol; 2010 May; 13(4):541-8. PubMed ID: 20047715
[TBL] [Abstract][Full Text] [Related]
32. Aripiprazole in an animal model of chronic alcohol consumption and dopamine D₂ receptor occupancy in rats.
Nirogi R; Kandikere V; Jayarajan P; Bhyrapuneni G; Saralaya R; Muddana N; Abraham R
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):72-9. PubMed ID: 23421566
[TBL] [Abstract][Full Text] [Related]
33. Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior.
De Carolis L; Schepisi C; Milella MS; Nencini P
Psychopharmacology (Berl); 2011 Dec; 218(4):749-59. PubMed ID: 21660444
[TBL] [Abstract][Full Text] [Related]
34. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.
Mace S; Taylor D
CNS Drugs; 2009 Sep; 23(9):773-80. PubMed ID: 19689167
[TBL] [Abstract][Full Text] [Related]
35. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.
Seeman P
Synapse; 2008 Dec; 62(12):902-8. PubMed ID: 18792990
[TBL] [Abstract][Full Text] [Related]
36. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Etievant A; Bétry C; Arnt J; Haddjeri N
Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
[TBL] [Abstract][Full Text] [Related]
37. [How do antipsychotics exert their effects on dopamine receptor subtypes?].
Inoue A; Nakata Y
Nihon Yakurigaku Zasshi; 1998 Dec; 112(6):351-61. PubMed ID: 10202760
[TBL] [Abstract][Full Text] [Related]
38. Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration.
Wee S; Wang Z; Woolverton WL; Pulvirenti L; Koob GF
Neuropsychopharmacology; 2007 Oct; 32(10):2238-47. PubMed ID: 17327886
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Neuropsychopharmacology; 2007 Jul; 32(7):1540-9. PubMed ID: 17164815
[TBL] [Abstract][Full Text] [Related]
40. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
Millan MJ; Iob L; Péglion JL; Dekeyne A
Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
